Nashville, Tenn. — Centerstone, the largest behavioral healthcare provider in Tennessee, has announced the promotion of David Ayer to Director of Clinical Research.
Ayer will work with a team of nationally known researchers who currently are managing clinical trials focusing on schizophrenia, depression, older adult needs, conduct disorders, homelessness, and nicotine, alcohol and methamphetamine abuse. Centerstone’s 20-person research staff, one of the largest of any behavioral healthcare provider in the country, coordinates approximately 40 clinical studies and numerous research projects. Centerstone’s research efforts include collaborations with a number of leading universities, including Vanderbilt and Duke, to answer questions surrounding the development and treatment of mental illness and to provide healthcare professionals with new options for treating patients.
“David is exceptionally fervent about discovering ways to assist Centerstone in identifying methods to help alleviate the stigma related to mental health issues,” said Thomas W. Doub, Ph.D., vice president for research. “We are pleased to reward his diligence and determination, and we look to him with confidence as he leads Centerstone’s research efforts.”
Ayer joined Centerstone in 2003 as administrator and research coordinator for the Institutional Review Board (IRB). The IRB collaborates with major pharmaceutical companies as well as colleges and universities to encourage and enhance quality mental health care. A member of the American Psychological Association, Ayer previously was a research professional for the Division of Psychopharmacology at the Psychiatric Hospital at Vanderbilt, where he currently holds a visiting researcher position.
He received a Bachelor of Science degree in psychology from Middle Tennessee State University in 1994 and a master’s of arts degree in clinical psychology from Middle Tennessee State University in 1998. Ayer is currently pursuing a Ph.D. in Behavior Analysis at Western Michigan University.